NEWTON,
Mass., Jan. 3, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company's senior management team will participate at the
42nd Annual J.P. Morgan Healthcare Conference in a
podium presentation on Wednesday, January
10 at 2:15 p.m. PT, followed
by a question-and-answer breakout session at 2:35 p.m. PT.
A live webcast of the presentation, along with accompanying
slides, can be accessed under "Events & Presentations" in the
Investor section of the Company's
website, http://investors.karyopharm.com/events-presentations,
and will be available for replay for 30 days following the
event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies. Since its founding, Karyopharm has been an industry
leader in oral Selective Inhibitor of Nuclear Export (SINE)
compound technology, which was developed to address a fundamental
mechanism of oncogenesis: nuclear export dysregulation.
Karyopharm's lead SINE compound and first-in-class, oral exportin 1
(XPO1) inhibitor, XPOVIO® (selinexor), is approved in
the U.S. and marketed by the Company in three oncology indications
and has received regulatory approvals in various indications in a
growing number of ex-U.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has a focused
pipeline targeting multiple high unmet need cancer indications,
including in multiple myeloma, endometrial cancer, myelodysplastic
syndromes and myelofibrosis. For more information about our people,
science and pipeline, please visit www.karyopharm.com, and follow
us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc. Any other trademarks
referred to in this release are the property of their respective
owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-42nd-annual-jp-morgan-healthcare-conference-302024595.html
SOURCE Karyopharm Therapeutics Inc.